Startup entity
Spectral AI is most often covered alongside BARDA, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 6 average consequence score is below the beat benchmark of 6.6 in the same window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Spectral AI is most often covered alongside BARDA, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 6 average consequence score is below the beat benchmark of 6.6 in the same window. funding accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Startup stories mentioning Spectral AI across the period from March 19, 2026 to March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 211 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spectral AI. Shared-story counts are live from our verified record — not editorial picks.
BARDA Award Announced
Spectral AI receives $31.7 million to accelerate DeepView development.
Clinical Validation Phase
Planned acceleration of clinical trials and R&D activities funded by the award.
Spectral AI, Inc. closed fiscal year 2025 with $19.7 million in research and development revenue and a robust $15.4 million cash balance. The company is now transitioning toward a commercial model, supported by newly introduced revenue guidance for the 2026 fiscal year.
Spectral AI has been awarded $31.7 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive funding supports the integration of AI-driven predictive analytics into burn and wound care, aiming to improve triage and treatment outcomes in both clinical and emergency response settings.
Spectral AI is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
